Solid Biosciences (SLDB) Capital Expenditures (QoQ) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 108.83% |
| Dec 31, 2025 | -62.64% |
| Sep 30, 2025 | -141.13% |
| Jun 30, 2025 | 428.75% |
| Mar 31, 2025 | 322.22% |
| Dec 31, 2024 | -325.00% |
| Sep 30, 2024 | 112.40% |
| Jun 30, 2024 | -186.58% |
| Mar 31, 2024 | -90.17% |
| Dec 31, 2023 | 1,174.47% |
| Sep 30, 2023 | 61.37% |
| Jun 30, 2023 | -172.13% |
| Mar 31, 2023 | 63.23% |
| Dec 31, 2022 | 180.94% |
| Sep 30, 2022 | -213.99% |
| Jun 30, 2022 | 27.27% |
| Mar 31, 2022 | 151.06% |
| Dec 31, 2021 | -190.07% |
| Sep 30, 2021 | 4,683.33% |
| Jun 30, 2021 | -65.71% |
| Mar 31, 2021 | -41.67% |
| Dec 31, 2020 | -25.00% |
| Sep 30, 2020 | -88.64% |
| Jun 30, 2020 | 1,180.00% |
| Mar 31, 2020 | -91.47% |
| Dec 31, 2019 | -0.77% |
| Sep 30, 2019 | -42.93% |
| Jun 30, 2019 | -41.68% |
| Mar 31, 2019 | 344.87% |
| Dec 31, 2018 | 111.85% |
| Sep 30, 2018 | -215.17% |
| Jun 30, 2018 | 221.28% |
| Mar 31, 2018 | 159.41% |
| Dec 31, 2017 | -203.31% |
| Sep 30, 2017 | 438.28% |
| Jun 30, 2017 | 1,793.75% |